Natera

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Natera 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTRA

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). 

CEO
Stephen Leonard Chapman
CEOStephen Leonard Chapman
Employees
6,140
Employees6,140
Headquarters
Austin, Texas
HeadquartersAustin, Texas
Founded
2003
Founded2003
Employees
6,140
Employees6,140

NTRA Key Statistics

Market cap
40.00B
Market cap40.00B
Price-Earnings ratio
-170.18
Price-Earnings ratio-170.18
Dividend yield
Dividend yield
Average volume
2.14M
Average volume2.14M
High today
High today
Low today
Low today
Open price
$278.47
Open price$278.47
Volume
0.00
Volume0.00
52 Week high
$279.63
52 Week high$279.63
52 Week low
$131.81
52 Week low$131.81

Stock Snapshot

Natera(NTRA) stock is priced at $279.32, giving the company a market capitalization of 40B. It carries a P/E multiple of -170.18.

Natera(NTRA) stock opened on 2026-07-06 at $278.47. The price climbed to — and dipped to —.

The Natera(NTRA)'s current trading volume is 0, compared to an average daily volume of 2.14M.

During the past year, Natera(NTRA) stock moved between $131.81 at its lowest and $279.63 at its peak.

During the past year, Natera(NTRA) stock moved between $131.81 at its lowest and $279.63 at its peak.

NTRA News

TipRanks 1h
Natera announces publication evaluating utility of Signatera

Natera (NTRA) announced the publication of new data in JAMA Oncology, evaluating the utility of Signatera, its personalized molecular residual disease test, in...

Simply Wall St 3d
Natera Lands New Trial Partnerships, Is The Upside Already Priced In?

Natera (NTRA) has drawn fresh investor attention after a series of partnerships and approvals, including new Phase 3 trial collaborations and regulatory clearan...

Natera Lands New Trial Partnerships, Is The Upside Already Priced In?
Nasdaq 7d
Natera Partners With Aveta Biomics On Phase 3 Head And Neck Cancer Trial

(RTTNews) - Natera, Inc. (NTRA), a clinical genetic testing company, and Aveta Biomics, Inc., an immuno-oncology company, on Monday announced a partnership to s...

Natera Partners With Aveta Biomics On Phase 3 Head And Neck Cancer Trial

Analyst ratings

88%

of 24 ratings
Buy
87.5%
Hold
12.5%
Sell
0%

People also own

Based on the portfolios of people who own NTRA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.